Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibitors targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis represent a significant advancement in cancer immunotherapy.
• The PD-1 pathway plays a crucial role in regulating immune responses and is implicated in tumor immune evasion.

Purpose of the Study:

• To provide an overview of the biology and function of the PD-1 pathway.
• To discuss the rationale for therapeutic inhibition of the PD-1/PD-L1 axis in lymphoma.
• To review current and emerging clinical trials of PD-1 pathway inhibitors in lymphoma.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of clinical trial data for PD-1 inhibitors in lymphoma.
• Evaluation of biomarkers for predicting treatment response.

Main Results:

• Studies have assessed PD-1, PD-L1/2 expression in various lymphoma subtypes, revealing prognostic implications.
• Clinical trials involving pidilizumab, nivolumab, and pembrolizumab in lymphoid malignancies are ongoing.
• Promising new agents targeting this pathway are under development.

Conclusions:

• Numerous clinical trials are investigating immune checkpoint inhibitors for various lymphoma subtypes.
• These trials will determine the role of these inhibitors as monotherapy and in combination regimens.
• Biomarker research is crucial for predicting patient response to PD-1 pathway blockade in lymphoma.